Philips Pharma Solutions provides comprehensive medical imaging core lab services for clinical trials and support for all major areas of drug and device research imaging. Our highly qualified team includes board-certified radiologists, sub-specialty experts, thought leaders and experienced technicians. All are dedicated to helping you design and implement the optimal protocol to acquire, evaluate and transfer accurate, quality data through an efficient, cost-effective and state-of-the-art global infrastructure.
We have vast experience in echocardiography (ECHO) and maintain a state-of-the-art ECHO processing infrastructure. Our experienced physicians perform all ECHO analyses, including quantification of cardiac chamber size, ventricular mass, cardiac function, volume and wall thickness. Display modes include 2-D, M-Mode, Doppler and Tissue Doppler. These procedures are based on the American Society for Echocardiography guidelines, which are widely applied to clinical research and practice.
As the pipeline of potential cancer treatments expands, the number of clinical trials utilizing imaging will continue to increase. Whether a trial is assessing longest diameter, sum of the products of diameters (SPD), tumor volume or other endpoints, we’re equipped to analyze data and deliver structural and volumetric measurements for a variety of oncology/hematology assessment criteria and imaging modalities. Experienced scientific and medical teams will also work closely with you to tailor your plan by implementing modifications to your published criteria. Additionally, we can provide specialized assessments of other structural or functional parameters through custom algorithms – offering robust and reliable solutions.
We have extensive expertise with both qualitative and quantitative central imaging analysis for muscle disease, arthritis and other bone diseases. For arthritis, measurements include scoring as well as quantitative and cartilage/bone endpoints.
We will work with your team to determine which endpoints are the right fit for your study; whether you are looking to verify mechanism of action via advanced parametric mapping or other quantitative measures, assess bone safety through DXA, or obtain more qualitative assessments by expert readers, we have you covered.
With the scientific expertise to perform standard and advanced MRI endpoints, our imaging core lab provides quantitative imaging analysis for metabolic disorders such as non-alcoholic steatohepatitis (NASH), diabetes, obesity and non-alcoholic fatty liver disease (NAFLD).
We consistently deliver imaging solutions for a wide variety of central and peripheral nervous system diseases, including Alzheimer’s disease, multiple sclerosis and stroke. Whether your trial requires standard assessments such as brain volume, hippocampal atrophy, white matter lesion measurement or more complex functional or molecular imaging assays, the right imaging solution will be determined by leveraging a scientific and medical teams’ experience and expertise.
You are about to visit a Philips global content page
Continue